Nishi Suryavanshi, PhD

Pune, India
Role: 
Staff
Clinical Research Site Coordinator, Deputy Director, BJGMC Clinical Research Site; Research Associate, Johns Hopkins School of Medicine

Dr. Suryavanshi is Clinical Research Site Coordinator and Deputy Director for the BJGMC-JHU CRS in Pune, India. She has 18 years of experience working in the ACTG and IMPAACT networks as a protocol team member, site co-investigator and lead behavioral science studies in TB, HIV, mental helath, substance use, and women’s health.In addition, she has been instrumental in implementing large NIH funded research projects with strong leadership qualities and site management skills.

Dr. Suryavanshi has established extensive networks with regional non-governmental organizations (NGOs) and local TB and HIV programs. She has developed and co-developed various social and behavioural projects. During the past 22 years, she has overseen the clinical research studies related to HIV/AIDS and TB at of BJGMC-JHU Clinical research site in Pune, India.

Dr. Suryavanshi completed a CDC grant to enhance the capacity of outreach workers catering to HIV-infected pregnant women to uptake PMTCT services using mHealth platform. She is leading a Hybrid trail for Alcohol reduction intervention among HIV and HIV/TB patients at two sites in Pune, India, an operational project assessing the implementation of 3HP TB preventive therapy among People Living with HIV and a longitudinal qualitative study to understand treatment experiences of children with drug resistant TB.

She has been selected as a mentor of the USAID PEER Mentorship program for women in TB research. Currently, she is mentoring 5 junior scientists from Johns Hopkins and Tulane University. She is also serving as a member of the Technical Advisory Committee of Capacity development in HIV and Mental health Research in Asia (D43 grant from Fogarty NIH)· She is Heading Behavioural and Social science Working Group, RePORT India consortium. Leading a training and mentoring committee for the JHUBI Clinical trials unit program. She has presented her work at national and international conferences and has published study findings in peer-reviewed journals with 70+ publications.

Dr. Suryavanshi attended the University of Pune, Maharashtra, India, where she earned her BSc in zoology, her MSc in Medical anthropology, and her Ph.D. in Anthropology. Additionally, she is a graduate of the Johns Hopkins University Summer Institute of Epidemiology and Biostatistics, where she studied the ethical issues related to human subjects research in developing countries.

Twelve month follow-up of the SWEN randomized controlled trials: Differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count

Post Date: 
2011-03-27
   |      |   
Clinical Sites: 
Publication: 
AIDS Care
Objectives: We previously reported combined analysis of 6-week and 6-month endpoints of three randomized controlled trials [Six Week Extended Dose Nevirapine (SWEN) trials] that compared extended-dose nevirapine through 6 weeks of age to single-dose nevirapine to prevent HIV transmission via...

Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus

Post Date: 
2011-02-01
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
The Journal of Infectious Diseases
Background: Maternal human immunodeficiency virus (HIV) RNA load, CD4 cell count, breast-feeding, antiretroviral use, and malaria are well-established factors associated with mother-to-child transmission (MTCT) of HIV; the role of maternal tuberculosis (TB), however, has not been well...

Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomized controlled trials

Post Date: 
2009-07-26
   |      |   
Clinical Sites: 
Publication: 
The Lancet
Background: UNICEF/WHO recommends that infants born to HIV-infected mothers who do not have access to acceptable, feasible, affordable, sustainable, and safe replacement feeding should be exclusively breastfed for at least 6 months. The aim of three trials in Ethiopia, India, and Uganda was...

Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants

Post Date: 
2009-01-01
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
PLOS One
Background: Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission. We assessed NVP-resistance in Indian infants enrolled in the “six-week extended-dose nevirapine” (SWEN) trial who received single-dose NVP (SD-NVP) or SWEN for prevention...

Repeated pregnancy in HIV positive Indian women with known HIV status

Post Date: 
2008-09-29
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
AIDS Care
HIV-positive women of reproductive age face challenges in decision making related to pregnancy. Understanding factors influencing repeat pregnancies in women with known HIV status are necessary to guide interventions and counseling strategies to better inform and support them. We compared...

Nurses’ health education program in India increases HIV knowledge and reduces fear

Post Date: 
2007-11-30
   |   
Countries: 
Publication: 
Journal of the Association of Nurses in AIDS Care
Few health care facilities are adequately prepared to manage and care for HIV/AIDS patients in India. Nurses play a critical role in patient care but are often ill-equipped to deal with their own fears of occupational risk and handle the clinical aspects of HIV/AIDS care, leading to stigma and...

Making the choice: the translation of global HIV and infant feeding policy to local practice among mothers in Pune, India

Post Date: 
2005-04-15
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
The Journal of Nutrition
In 2003, India had over 5.1 million infected individuals living with HIV/AIDS. The percentage of all HIV cases attributed to perinatal transmission has been increasing steadily from 0.33% of total cases in 1999 to 2.80% in 2004. Recent statistics indicate that over 130,000 infants have been...

Pages